InSysBio to participate in Biomarkers for Alzheimer’s Disease Summit

August 6, 2021

August 6, 2021

InSysBio will take part in Annual Biomarkers for Alzheimer’s Disease Summit, Digital Event which is going to be held August 24-26, 2021. InSysBio will present its Neurodegeneration modeling issues and Alzheimer’s Disease Platform update at its Virtual Booth!
Moreover, Tatiana Karelina, Head of Neurodegenerative Diseases Modeling Team, will give a talk on the topic “Mechanistic modeling approach to prediction and analysis of clinical trial results in neurodegeneration area”.

Tatiana is going to shed the light on the following points:

  • Quantitative system pharmacology (QSP) modeling of clinical trials facilitates interpretation of information provided by biomarkers.
  • QSP methods allows for investigation of interaction between pathological mechanisms, biomarkers and treatment: example for aducanumab clinical trial.
  • Combinatorial therapy efficacy on endpoints, intrinsic mechanisms and biomarkers can be potentially predicted by QSP.

10:35 EDT | 07:35 PDT on Wednesday, August 25.

Visit our Virtual Booth and follow our speaker!

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 120 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit